Orchestra BioMed (OBIO) | Stock Overview & Key Data
Orchestra BioMed Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $23.39 on April 3, 2023
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Orchestra BioMed
OBIO
|
242.86M Micro-cap | -1.76% | -2.99% | -10.96% | -18.24% | -9.51% | 37.19% | -75.14% | -61.44% | -51.73% | -51.73% | -51.73% |
|
Vertex
VRTX
|
109.45B Large-cap | -2.49% | -1.11% | -12.54% | -1.86% | -5.98% | 1.24% | 34.08% | 113.19% | 376.31% | 717.28% | 1,190.86% |
|
Regeneron
REGN
|
80.98B Large-cap | -5.03% | -15.02% | -23.79% | -18.77% | -22.36% | 25.39% | -16.92% | 20.10% | 53.41% | 959.24% | 4,557.42% |
|
Adagene
ADAG
|
243.81M Micro-cap | -8.87% | -7.38% | 14.53% | 70.35% | 84.24% | 104.64% | 198.50% | -71.19% | -85.65% | -85.65% | -85.65% |
|
Third Harmonic Bio
THRD
|
242.79M Micro-cap | 0.00% | -1.28% | 4.47% | 56.40% | 56.40% | -53.82% | -70.11% | -70.11% | -70.11% | -70.11% | -70.11% |
|
Voyager Therapeutics
VYGR
|
240.78M Micro-cap | -6.27% | -7.47% | -13.49% | -4.77% | -10.92% | 41.24% | -65.93% | -8.08% | -71.12% | -78.62% | -78.62% |
Ownership & Short Interest
Calculate Your Orchestra BioMed Investment Returns
Long-Term Investment Performance Analysis
Orchestra BioMed stock price in Jan 2020 was $8.10, A $1,000.00 lump sum investment in Orchestra BioMed made 6 years ago would be worth approximately $481.48 today, representing a negative return of -51.85%. This translates to an annualized return (CAGR) of -10.85%.
6 Years 4 Months Investment Scenario (Jan 2020 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is OBIO's 52-week high and low?
- In the last 52 weeks, Orchestra BioMed reached a high of $5.42 (on November 26, 2025) and a low of $2.20 (on September 24, 2025).
- What is the market cap and P/E ratio for OBIO?
- Curious about Orchestra BioMed's size and valuation? Its market capitalization stands at 242.86M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -2.47.
- Does OBIO pay dividends? If so, what's the yield?
- As for dividends, Orchestra BioMed isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Orchestra BioMed's main competitors or similar companies to consider before investing?
When looking at Orchestra BioMed, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology 1.24% 34.08% Regeneron
REGN80.98B Healthcare Biotechnology 25.39% -16.92% Adagene
ADAG243.81M Healthcare Biotechnology 104.64% 198.50% Third Harmonic Bio
THRD242.79M Healthcare Biotechnology -53.82% -70.11% Voyager Therapeutics
VYGR240.78M Healthcare Biotechnology 41.24% -65.93% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Orchestra BioMed Holdings, Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Orchestra BioMed's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -109.41%, the Debt to Equity ratio from the most recent quarter is 25.17, and its Gross Profit Margin stands at 99.84%.
- What is the recent revenue and earnings growth for OBIO?
- Looking at Orchestra BioMed's growth, its revenue over the trailing twelve months (TTM) was $33M. Compared to the same quarter last year (YoY), quarterly revenue grew by 12,120.20%, and quarterly earnings saw a YoY growth of 12,120.16%.
- How much of OBIO stock is held by insiders and institutions?
- Wondering who owns Orchestra BioMed stock? Company insiders (like executives and directors) hold about 27.92% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 38.23%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.